Ab­b­Vie bets $48M up­front for ear­ly-stage an­ti­body tar­get­ing chron­ic in­flam­ma­tion

Ab­b­Vie is mak­ing good on its plans to search for new mech­a­nisms of ac­tion, this time with French biotech OSE Im­munother­a­peu­tics for a mon­o­clon­al an­ti­body tar­get­ing in­flam­ma­tion.

Ab­b­Vie will pay $48 mil­lion up­front to OSE for an ex­clu­sive glob­al li­cense to de­vel­op, man­u­fac­ture and com­mer­cial­ize the an­ti­body, dubbed OSE-230. OSE is el­i­gi­ble for an­oth­er $665 mil­lion in mile­stones as well as tiered roy­al­ties on glob­al net sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.